‘Storm in a teacup’: Why the Imugene share price is lifting 14% today

What did Imugene reveal in its letter to shareholders today?

| More on:
Nothing to see here, just a storm in a teacup as far as this boy and girl are concerned, sipping tea in their living room.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Imugene shares are soaring nearly 14% today 
  • The S&P/ASX 200 Health Care Index, in contrast, is slipping nearly 1% 
  • The company's executive chair and CEO wrote to shareholders highlighting the company is "as strong as ever" 

The Imugene Limited (ASX: IMU) share price is soaring ahead today.

At the time of writing, Imugene shares are swapping hands for 22.8 cents, a 13.75% gain. In contrast, the S&P/ASX 200 Health Care Index (ASX: XHJ) is 0.87% in the red today. Meanwhile, the S&P/ASX 200 Index (ASX: XJO) is falling 0.1%.

Let’s take a look at the letter from the company to shareholders released today.

Imugene share price lifts

Imugene has written to shareholders to discuss the company’s share price in the last few months. For perspective, Imugene shares have dived 43% year to date.

Company leaders said Imugene is “as strong as it has ever been in its history”. Imugene highlighted it has $100 million in cash and three unique platform technologies supporting six unique assets.

Imugene informed shareholders it expects to have 10 clinical studies supported by five to six United States Food and Drug Administration (FDA) investigational new drug applications. The drugs are targeting greater than 10 disease areas. The company also has two supply agreements with major pharmaceutical companies and two industry collaborations.

Imugene advised the market that multiple shareholders have reached out to the company about the recent cancelling of a supply agreement with MSD. On 2 May, the company’s share price plunged nearly 14% on the back of this news. In a letter dated today, executive chair Paul Hopper and CEO and managing director Leslie Chong said:

The reaction to this has been out of all proportion to the news, and is really a storm in a teacup.

We recently announced that this trial is open ahead of schedule and can be expedited by obtaining the drug elsewhere, the cost of which is not material.

Turbulent times

Imugene noted “we are living in turbulent times” and biotech share prices have dropped dramatically since December last year. The company highlighted the sector has plunged about 65% from its peak in February 2021. Furthermore, April was the worst month on record for US biotech shares since 1997. Hopper and Chong added:

In addition, investors around the world have been spooked by the Ukraine Russia tensions, hawkish comments from the US Federal reserve, stubborn inflation and a worsening COVID situation in China.

Hopper and Chong said they remain and will continue to be large shareholders of the company and emphasised the “exciting times” ahead.

Share price snapshot

The Imugene share price has descended nearly 44% in the past year, but it is up 1.1% in a month.

In comparison, the benchmark ASX index has returned 2% over the past year.

In the past week alone, Imugene shares have surged 30%.

Imugene has a market capitalisation of $1.16 billion based on the current share price.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two happy scientists analysing test results.
Healthcare Shares

Up 13% in a month, Polynovo share price bounces back after being dumped from ASX 200

What's going on with the Polynovo share price?

Read more »

health workers shake hands and congratulate each other on good news
Share Gainers

This ASX All Ordindaries healthcare share is ripping 17% higher amid a new contract win

Investors seem to like the contract win from this healthcare player.

Read more »

Two researchers discussing results of a study with each other.
Healthcare Shares

Here’s how ASX 200 healthcare shares performed in June

Healthcare shares were a tad ill in June.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

What’s the outlook for the CSL share price in July?

We take a look at what the experts are saying about the biotech company's shares.

Read more »

Photo of a group of scientists cheering while working in a lab as the Race Oncology share price skyrockets today on positive study results
Healthcare Shares

Why is the Race Oncology share price soaring 13% today?

New trial results have excited ASX investors.

Read more »

Rising arrow on a blue graph symbolising a rising share price.
Healthcare Shares

Starphama share price lunges 5% on product relaunch

Early support for Starphama on Thursday has it off to a great start.

Read more »

Man with rocket wings which have flames coming out of them.
Healthcare Shares

Why is the Paradigm share price rocketing 20% higher today?

The Paradigm share price is having a very strong day...

Read more »

A businessman presents a company annual report in front of a group seated at a table
Healthcare Shares

Own Immutep shares? Here are 3 takeaways from the company’s investor update

Investors were mute to the update.

Read more »